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A comprehensive synthetic approach, previously introduced by this laboratory for the localization of the 
full profile of the continuous antigenic sites on proteins, was applied here to localize the continuous sites 
of ragweed allergen, Ra3, that are recognized by human anti-Ra3 IgE antibodies. The following 10 uniform 
and overlapping peptides were synthesized and purified: l-15, 1 l-25, 21-35, 3145, 41-55, 51-65, 61-75, 
71-85,81-95 and 91-101. Quantitative radiometric titrations of protein and peptide adsorbents with human 
IgE, established the full profile of allergenic (IgE binding) sites on Ra3. It was found that Ra3 has four 
continuous allergenic sites. Antibodies prepared against the IgE binding peptides bound to native Ra3. The 
findings are briefly discussed in relation to other protein antigenic structures and in terms of design of vac- 
cines using synthetic sites. 
Allergen Allergenic sites IgE antibodies 
1. INTRODUCTION 
Desensitization strategies against allergens 
presently involve immunization protocols that 
employ purified or crude allergen extracts. 
Although the mechanism of this protection is not 
really understood, it is believed to result from 
elevation, due to allergen inoculation, of the titer 
of anti-allergen IgG antibodies which can compete 
for the allergen with anti-allergen IgE antibodies 
and may alleviate the allergic reaction or decrease 
its severity. However, frequently immunization 
with allergens causes side reactions such as 
anaphylactic shock, delayed Type I IgE-mediated, 
arthus or systemic reactions. It would, therefore, 
be desirable to investigate alternatives to present 
vaccination methods. The possibility of using syn- 
thetic peptide vaccines for clinical desensitization 
is very attractive because it would be expected to 
cause little or no side reactions. In order for this 
approach to be successful, the regions on an 
allergen that bind IgE antibodies need to be 
* To whom correspondence should be addressed Previously, this laboratory had introduced [9] a 
Ragweed allergen Ra3 Synthetic peptides 
localized and then these synthetic regions can be 
designed into effective immunogens. However, lit- 
tle is known about the submolecular immune 
recognition of allergens and, indeed, the full pro- 
file of the regions on an allergen that are recogniz- 
ed by IgE antibodies has not been determined. This 
paper describes the first phase of our studies on 
this subject, namely the location of the allergenic 
(IgE binding) sites, using a ragweed allergen as a 
model. 
Ragweed pollen is one of the most common 
causative agents of seasonal hay fever in the 
United States. At least 4 different protein allergens 
(namely antigen E, antigen K, Ra3, and Ra5) have 
been isolated from ragweed pollen [l-5]. One of 
these major allergens, Ra3, is a basic glycoprotein 
having a single polypeptide chain composed of 101 
amino acid residues [6]. Ra3 is highly allergenic in 
about 30-50% of ragweed sensitive individuals 
[7,8]. The anaphylactic phenomena which result in 
the symptoms of organ shock are initiated by reac- 
tion of allergen with IgE antibodies elicited in 
response to the allergen. 
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comprehensive synthetic approach designed to 
systematically localize the full profile of the con- 
tinuous sites on a protein. The approach consists 
of the synthesis and examination of the im- 
munochemical activities of a series of consecutive 
overlapping peptides, of uniform size and 
overlaps, that encompass the entire protein chain. 
This strategy has been applied to localize, for 
several prbteins, the continuous sites recognized by 
antibodies and by T cells [9-171. It should be 
noted that this strategy has been designed 
specifically for the localization of continuous an- 
tigenic sites (for definition of ‘continuous’ and 
‘discontinuous’ antigenic sites, see [lS]). A more 
detailed discussion of this strategy has already 
been reported [9, lo]. In the present paper we 
report the application of this strategy to Ra3. Ten 
overlapping peptides comprising the entire Ra3 
molecule have been synthesized and their binding 
to human IgE antibodies permitted the localization 
of the allergenic sites to within fairly small regions 
on the allergen. 
2. MATERIALS AND METHODS 
Human sera were obtained from 3 individuals 
with known severe allergy to ragweed. The sera 
contained 1500-3800 ng IgE antibodies to 
ragweed allergens/ml. Ra3, rabbit anti-human IgE 
antiserum and polyvalent rabbit anti-ragweed an- 
tiserum were obtained from the Research 
Resources Branch, National Institute of Allergy 
and Infectious Diseases, National Institutes of 
Health, Bethesda, MD. Antibodies to synthetic 
peptides were prepared in outbred mice by im- 
munization with an emulsion of the free (i.e. 
without conjugation to a carrier) peptides 
(25 pg/mouse) in complete Freund’s adjuvant. 
Each peptide was injected into 4 mice. The mice 
were boosted by a similar dose of the respective 
peptide at 3 weeks and thereafter monthly. Test 
bleeds were obtained at 2-week intervals and the 
antisera from the 4 mice immunized with a given 
peptide were pooled. The antisera studied here 
were from the 9%day bleeds. 
The synthetic strategy is shown schematically in 
fig. 1. Solid-phase synthesis of the Ra3 peptides, 
from the known primary structure of Ra3 [6], was 
performed by procedures similar to those detailed 
1 101 
1 15 21 35 41 55 61 75 81 95 
----- 
11 25 31 45 51 65 71 85 91101 
----- 
Fig.1. Schematic presentation of the synthetic 
overlapping peptides strategy that was employed for the 
delineation of the continuous allergenic sites of Ra3. The 
strategy relied on the synthesis of the entire polypeptide 
chain in 15-residue p ptides (except for peptide 91-lol), 
each overlapping its 2 adjacent neighbors by 5 residues 
on both sides. 
in [ 191. The peptides were purified by gel filtration 
on Sephadex G-25, followed by ion-exchange 
chromatography on CM-Sephadex (C-50) or 
DEAE-Sephadex (A-50) [19,20]. Their purity was 
checked by peptide mapping [21], and by amino 
acid analysis of HCI [21] and 3 M toluene-p- 
sulfonic acid [22] hydrolyzates. Amino acid com- 
positions of the purified peptides agreed well with 
those expected from their covalent structures. 
The IgG fractions of rabbit anti-IgE antisera 
were prepared as described in [20] and were la- 
belled with “‘1 (Amersham, Arlington Heights, 
IL) by a chloramine-T procedure [23]. Unbound 
lz51 was separated from the radiolabelled samples 
by gel filtration on Sephadex G-15 (Pharmacia, 
Piscataway, NJ). The proteins [Ra3, or unrelated 
control proteins human adult hemoglobin (Hb) 
and bovine serum albumin (BSA)] and the syn- 
thetic peptides were coupled to CNBr-activated 
Sepharose CL 4B (Pharmacia) under the optimum 
conditions previously described [24]. 
The binding of human IgE antibodies to the 
Sepharose adsorbents was determined by the dou- 
ble antibody quantitative immunoadsorbent titra- 
tion assay [25] using human serum prediluted 
l/1000 (v/v) with PBS containing 0.1% BSA, 
followed by 1251-labelled immune IgG of rabbit 
anti-human IgE antiserum. Non-specific adsorp- 
tion was determined by titrating equal volumes of 
uncoupled Sepharose, BSA-Sepharose, Hb- 
Sepharose and Sepharose adsorbents of 2 
unrelated synthetic Hb peptides of equal size (i.e. 
al-15 and 91-105 [9,10]). The specificity of an- 
tibody binding to peptide adsorbents was confirm- 
ed by inhibition experiments. In these studies, the 
appropriate adsorbents and labelled IgG fractions 
were allowed to react as above in the presence of 
either Ra3 (0.5 mg/ml) or unrelated proteins, Hb 
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and BSA (1 mg/ml). After correction for non- 
specific binding, the amount of radioactivity 
bound in the presence of Ra3 (inhibited values) 
was expressed as a percentage of that bound in the 
absence of inhibitor (uninhibited values) and com- 
pared to the effects of the unrelated proteins. An- 
tibodies in mouse antipeptide antisera were 
assayed for binding to Ra3 and peptide by a plate 
assay [26]. To guard against removal of peptide 
during washing of the plates, the peptides were 
used in the plate assay as conjugates onto succinyl 
BSA. The coupling procedure has been described 
]271. 
3. RESULTS AND DISCUSSION 
The results of quantitative immunoadsorbent 
titrations are summarized in table 1, which gives 
the maximum binding values of human IgE an- 
Table 1 
Binding of human anti-Ra3 IgE antibodies to synthetic 
Ra3 peptides 
Protein or IgE antibodies bound 
peptide adsorbent 
A cpm % relative to Ra3 
Ra3 17360 100 
l-15 2590 14.9 
1 l-25 920 5.3 
21-35 4580 26.4 
31-45 4150 23.9 
41-55 430 2.4 
51-65 5340 30.8 
61-75 485 2.8 
71-85 3970 22.9 
81-95 310 1.8 
91-101 0 0 
The results summarize the maximum binding values 
obtained in the plateau by quantitative 
radioimmunoadsorbent titrations. The values represent 
the average of 3 or more replicate analyses which varied 
k 1.5% or less. Human IgE binding was determined by 
a double antibody assay using ‘251-Iabelled immune IgG 
(lo5 cpm) from rabbit anti-human IgE antiserum. 
Baseline control antigens were bovine serum albumin, 
human hemoglobin, sperm whale myoglobin and 
hemoglobin synthetic peptide (~1-15. Values not 
significantly >O by Student’s f-test (P < 0.05) are 
reported as 0 
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tibodies to Ra3 and its synthetic peptides. Several 
peptide adsorbents showed very little (below 3%) 
or no binding activity of IgE antibodies 
throughout the titration range. These were pep- 
tides 41-55, 61-75, 81-95 and 91-101. On the 
other hand, the other peptides exhibited con- 
siderable antibody binding capacity. The binding 
of antibodies to these peptide-adsorbents was com- 
pletely inhibited by the addition of free uncoupled 
Ra3 to the reaction (not shown) but not by 
unrelated proteins (BSA, Hb). Also, none of the 
peptides bound labelled IgG from pre-immune sera 
of mouse and rabbit or antibodies to unrelated 
proteins (BSA, Hb and sperm whale myoglobin). 
These findings indicated unambiguously that an- 
tibodies reacting with the peptide adsorbents are 
specific for Ra3. 
It should be cautioned that the calculated sum of 
the activities of the peptides with each of the an- 
tisera must be considered in the context of the 
structures of the peptides and their overlaps, which 
were designed to detect antigenic sites located in 
the overlapping regions between adjacent peptides 
(see below). Thus adjacent overlapping peptides 
that have similar activities may be expressing iden- 
tical specificities (e.g. peptides 21-35 and 31-45 
each absorbs the activity towards the other). Final- 
ly, antisera raised against he active peptides 1-15, 
21-35, 31-45, 51-65 and 71-85 were examined 
for their ability to bind to native Ra3. The results 
are summarized in table 2. In each case, anti- 
peptide antibodies bound to native allergen. 
The antibody binding activities of the synthetic 
peptides have permitted the localization of the full 
allergenic profile of Ra3. The finding that several 
of the peptides exhibited very low (below 3%) 
antibody-binding activity (table 1) indicated the 
presence of very low antibody responses to regions 
outside the 4 immunodominant sites. These an- 
tibodies were difficult to quantitate because of 
their presence in very low amounts. Thus, regions 
of the Ra3 that are apparently inactive may be 
recognized by amounts of antibodies that are 
below detection levels by these sensitive methods. 
Similar results have been obtained with other pro- 
teins [10,12,28,29] where low antibody levels 
(below l-2%) were observed for regions outside 
the immunodominant antigenic sites and these 
have been termed as ‘general background’ 
responses [30]. 
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Table 2 
Binding to Ra3 of anti-peptide antibodies 
Immunizing 
peptide 






I-15 3119 3313 
21-35 6320 6340 
31-45 3140 3840 
51-65 3340 3510 
71-85 18670 17530 
Anti-peptide antisera were elicited in 4 outbred mice 
each by immunization with free (i.e. not coupled to any 
carrier) peptides. For RIA plate assay, the peptides were 
used as conjugates on succinylated bovine serum 
albumin. Mouse anti-peptide antibodies were assayed 
for binding to Ra3 by a solid-phase plate RIA. The assay 
involved briefly the following order of steps. A solution 
of Ra3, peptide conjugates or unrelated control antigens 
(5 pg in 50~1 PBS) was added to each well, plates 
incubated (1 h, 37”C), washed (5 x with PBS), blocked 
with 100~1 of 2% BSA (1 h, 37”C), washed (5 x with 
PBS), incubated (2.5 h, 37°C) with 50 pl of anti-peptide 
antiserum (prediluted l/l000 with PBS/O.l% BSA), 
washed (5 x with PBS), incubated (2.5 h, 37°C) with 
rabbit anti-mouse (IgG + IgM) prediluted l/1000 with 
PBS/O.l% BSA), washed (5 x with PBS), incubated 
(2 h, room temperature) with 50~1 ‘251-labelled protein 
A (2 x lo5 cpm) in PBS, washed (5 x with PBS) and 
finally the wells were cut out and counted on a gamma 
counter. The results were corrected for non-specific 
binding (0.3-0.5% of total label) of antibody on plates 
coated with BSA, Hb or conjugates of Hb peptide 
~~1-15. Values are expressed as the mean cpm of r2?- 
labelled protein A bound, and they varied ? 1.4% or 
less (PBS: 0.15 M NaCl in 0.01 M sodium phosphate 
buffer, pH 7.2) 
This is the first allergen for which the full IgE 
submolecular recognition profile has been deter- 
mined. The fact that anti-peptide antibodies bound 
to native Ra3 suggests that these synthetic regions, 
which are also the target of IgE recognition, may 
be used in the future as the basis for design of syn- 
thetic vaccines. These investigations will be carried 
out. 
The present mapping of the allergenic profile of 
Ra3 shows that the allergen has discrete sites that 
are recognized by human IgE antibodies (table 1). 
These findings are consistent with what is known 
about protein antigenic structures [28-311 and do 
not support the recent proposals that protein an- 
tigenic sites are not discrete areas on a protein but 
rather represent a ‘continuum of recognition’ over 
the entire protein molecule and that localization of 
antigenic sites and their synthesis are a meaningless 
endeavor [32]. It should be noted that the antigenic 
sites of Ra3 reported here are not predictable from 
the empirical approach based on hydrophilicity 
analysis of the sequence [33]. Indeed, the region 
88-93 was predicted [33] to be an antigenic site 
because it has the highest average hydrophilicity in 
the protein. Our findings clearly do not confirm 
this prediction. Although protein antigenic sites 
are exposed [19,20,28-311, exposure is not a suffi- 
cient criterion for antigenicity [28,29]. Further- 
more, antigenic sites are not necessarily in highly 
hydrophilic locations. Hydrophobic interactions 
provide major contributions to the binding energy 
[28]. The lack of correspondence between regions 
of hydrophilic maxima and antigenic site locations 
in several proteins has been discussed [3 1,341. 
Recent studies from this laboratory on the T-cell 
recognition of proteins [ 13-17,351 have led to the 
conclusion [35,36] that the design of effective vac- 
cines using small synthetic peptides must take into 
account the role of the T-cell recognition in the 
responses to protein antigens and the regulation of 
these responses. Our work is now directed to the 
localization of the submolecular profile of the 
regions recognized on Ra3 by T cells. 
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